TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV

NCT01281813 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

145

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1 Infections

Interventions

DRUG: Darunavir
DRUG: Ritonavir

Sponsor

Janssen Sciences Ireland UC